Novavax
NVAX
#5751
Rank
ยฃ0.84 B
Marketcap
ยฃ5.18
Share price
0.73%
Change (1 day)
-20.31%
Change (1 year)

Revenue for Novavax (NVAX)

Revenue in 2025 (TTM): ยฃ0.78 Billion

According to Novavax's latest financial reports the company's current revenue (TTM ) is ยฃ0.76 Billion. In 2024 the company made a revenue of ยฃ0.54 Billion a decrease over the revenue in the year 2023 that were of ยฃ0.54 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Novavax from 1996 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) ยฃ0.78 B43.81%
2024 ยฃ0.54 B-0.13%
2023 ยฃ0.54 B-52.74%
2022 ยฃ1.15 B35.63%
2021 ยฃ0.84 B143.38%
2020 ยฃ0.34 B2351.7%
2019 ยฃ14.23 M-47.31%
2018 ยฃ27.01 M17.1%
2017 ยฃ23.06 M85.39%
2016 ยฃ12.44 M-49.14%
2015 ยฃ24.46 M24.22%
2014 ยฃ19.69 M55.32%
2013 ยฃ12.67 M-7.17%
2012 ยฃ13.65 M44.53%
2011 ยฃ9.44 M4153.06%
2010 ยฃ0.22 M10.63%
2009 ยฃ0.2 M-72.34%
2008 ยฃ0.72 M10.52%
2007 ยฃ0.65 M-72.52%
2006 ยฃ2.39 M-44.2%
2005 ยฃ4.28 M-7.83%
2004 ยฃ4.64 M-29.45%
2003 ยฃ6.58 M-25.62%
2002 ยฃ8.85 M-46.63%
2001 ยฃ16.59 M900.94%
2000 ยฃ1.65 M123.29%
1999 ยฃ0.74 M76.41%
1998 ยฃ0.42 M15.26%
1997 ยฃ0.36 M108.47%
1996 ยฃ0.17 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Agenus
AGEN
ยฃ80.13 M-89.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ1.81 B 135.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
ยฃ0.56 B-26.71%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
ยฃ0.44 B-41.44%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
ยฃ43.60 B 5,574.64%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
ยฃ47.10 B 6,029.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
ยฃ42.28 B 5,403.30%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
ยฃ31.77 B 4,034.68%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
ยฃ1.95 M-99.75%๐Ÿ‡บ๐Ÿ‡ธ USA